Arcutis Biotherapeutics, Inc. increased its Board of Directors from nine to ten members and appointed Christopher Peetz as a new Class III director, effective July 15, 2026. Mr. Peetz, a biopharmaceutical executive with experience at Mirum Pharmaceuticals and Tobira Therapeutics, will receive an initial stock option award for 21,486 shares and is eligible for a prorated annual equity award valued at approximately $350,000 and a $50,000 cash retainer. Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing therapies for chronic inflammatory skin diseases.

Arcutis Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where stockholders' votes on three proposals, including the election of Class III directors (Patrick J. Heron, Neha Krishnamohan, and Todd Franklin Watanabe), the ratification of andhesion to Ernst & Young LLP as independent auditor, and a voting on a non-binding advisory basis of executive officer compensation. The Board of Directors approved revisions to the Amended and Restated Non-Employee Director Compensation Program, Board members are compensated with annual cash and equity compensation. Arcutis Biotherapeutics, Inc. is a biopharmaceutical company that develops and commercializes commercial-stage products for inflammatory and inflammatory-related skin diseases.